Treatment of malignant hypercalcaemia with clodronate.

We have assessed the effects of clodronate (dichloromethylene diphosphonate; Cl2MDP 0.8-3.2g daily by mouth for up to 3 months) in 17 episodes of hypercalcaemia and osteolysis due to carcinoma. Clodronate reduced serum calcium in 14 episodes and bone resorption in all patients. These remained suppre...

Descripción completa

Detalles Bibliográficos
Autores principales: Percival, R. C., Paterson, A. D., Yates, A. J., Beard, D. J., Douglas, D. L., Neal, F. E., Russell, R. G., Kanis, J. A.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1985
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977044/
https://www.ncbi.nlm.nih.gov/pubmed/3158326

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1977044/
https://www.ncbi.nlm.nih.gov/pubmed/3158326

Ejemplares similares